How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

EU Beating Cancer Plan, EBCP access cancer citizens healthcare molecular diagnostics patient personalised medicine policy framework reimbursement screening treatment unmet medical need

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
25 Aug 2022
Historique:
received: 19 07 2022
revised: 16 08 2022
accepted: 19 08 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices-such as population-level screening for lung cancer-are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.

Identifiants

pubmed: 36141230
pii: healthcare10091618
doi: 10.3390/healthcare10091618
pmc: PMC9498919
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer Med. 2021 Apr;10(7):2396-2422
pubmed: 33650320
Nat Rev Clin Oncol. 2021 Mar;18(3):135-151
pubmed: 33046839
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):858-67
pubmed: 23703507
Biomed Hub. 2017 Nov 21;2(Suppl 1):16-21
pubmed: 31988925
Crit Rev Oncol Hematol. 2020 Feb;146:102858
pubmed: 31918343
Eur J Cancer. 2020 Feb;126:141-158
pubmed: 31928887
Int J Epidemiol. 2020 Aug 1;49(4):1294-1306
pubmed: 32830255
Health Policy. 2021 Mar;125(3):307-319
pubmed: 33388158
Cancers (Basel). 2022 May 27;14(11):
pubmed: 35681651
Biochim Biophys Acta. 2015 Dec;1856(2):189-210
pubmed: 26297204
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1528-1535
pubmed: 33656221
BMC Cancer. 2018 Mar 9;18(1):269
pubmed: 29523116
Future Oncol. 2020 May;16(13):859-868
pubmed: 32292062
J Thorac Dis. 2018 May;10(Suppl 13):S1556-S1563
pubmed: 29951306
Oncologist. 2020 Mar;25(3):e598-e601
pubmed: 32162818
Cancer J. 2012 Mar-Apr;18(2):176-84
pubmed: 22453019
Cancer Discov. 2021 Apr;11(4):858-873
pubmed: 33811121
Health Policy. 2020 Jan;124(1):69-74
pubmed: 31812325
Br J Cancer. 2020 Mar;122(7):1109-1117
pubmed: 32066910
Eur Respir J. 2016 Sep;48(3):889-902
pubmed: 27174888
Eur J Health Econ. 2010 Jan;10 Suppl 1:S85-90
pubmed: 20012128
Breast. 2021 Feb;55:79-90
pubmed: 33360479
Nat Med. 2022 Apr;28(4):666-677
pubmed: 35440720
Front Public Health. 2020 Feb 18;8:29
pubmed: 32133335
J Am Coll Surg. 2021 Apr;232(4):600-605
pubmed: 33346080
Health Policy. 2022 Sep;126(9):879-888
pubmed: 35750552
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):679-680
pubmed: 34329625
Acta Dermatovenerol Croat. 2015 Apr;25(1):1-7
pubmed: 28511743
Cancers (Basel). 2020 Jun 24;12(6):
pubmed: 32599792
N Engl J Med. 2018 May 03;378(18):1734-1740
pubmed: 29580179
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMJ. 2020 Feb 10;368:m127
pubmed: 32041693
BioDrugs. 2020 Apr;34(2):159-170
pubmed: 31792843
Contemp Oncol (Pozn). 2021;25(1):53-56
pubmed: 33911982
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
J Thorac Oncol. 2022 Feb;17(2):186-193
pubmed: 35074225
Rev Prat. 2020 Oct;70(8):844-848
pubmed: 33739681
Eur J Health Econ. 2010 Jan;10 Suppl 1:S115-29
pubmed: 20012129
Cancers (Basel). 2021 Feb 02;13(3):
pubmed: 33540773
World J Gastroenterol. 2009 Dec 21;15(47):5907-15
pubmed: 20014454
Dermatol Ther (Heidelb). 2022 May;12(5):1157-1165
pubmed: 35426606
Dermatol Pract Concept. 2021 Jul 01;11(Suppl 1):e2021164S
pubmed: 34447613
Contemp Oncol (Pozn). 2021;25(1):45-52
pubmed: 33911981
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Nuklearmedizin. 2021 Jun;60(3):205-208
pubmed: 34107536
Colorectal Dis. 2020 Dec;22(12):1965-1973
pubmed: 32737954
N Engl J Med. 2022 Jun 16;386(24):2261-2272
pubmed: 35657320
Tumori. 2012 Mar-Apr;98(2):204-9
pubmed: 22677985
Eur J Cancer. 2020 Mar;127:191-206
pubmed: 31932175
Cancers (Basel). 2021 Aug 04;13(16):
pubmed: 34439082
J Thorac Oncol. 2021 Jan;16(1):21-29
pubmed: 33384058
BMC Cancer. 2013 Jul 05;13:329
pubmed: 23826976
Cancers (Basel). 2020 Jul 21;12(7):
pubmed: 32708268
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1410-1417.e9
pubmed: 32898707
Eur J Cancer. 2016 Aug;63:201-17
pubmed: 27367293
Eur J Cancer. 2019 Feb;108:25-32
pubmed: 30605822
Eur J Health Econ. 2010 Jan;10 Suppl 1:S21-6
pubmed: 20012133
Cancer Control. 2022 Jan-Dec;29:10732748211056692
pubmed: 35000418
Health Policy. 2016 Dec;120(12):1378-1382
pubmed: 27823827
EPMA J. 2010 Dec;1(4):529-34
pubmed: 23199107
Eur J Cancer. 2021 Nov;157:308-347
pubmed: 34560371
J Thorac Dis. 2017 Mar;9(3):448-451
pubmed: 28449441
BMC Cancer. 2019 Mar 8;19(1):214
pubmed: 30849964
Eur J Health Econ. 2010 Jan;10 Suppl 1:S1-3
pubmed: 20012130
Transl Lung Cancer Res. 2020 Jun;9(3):887-897
pubmed: 32676354
Cancers (Basel). 2021 Oct 26;13(21):
pubmed: 34771526
SAGE Open Med. 2020 May 20;8:2050312120922029
pubmed: 32547747
Front Oncol. 2021 May 07;11:658054
pubmed: 34026637
Int J Cancer. 1997 Feb 7;70(4):396-400
pubmed: 9033645
Cancer. 2021 Jul 1;127(13):2181-2183
pubmed: 33788953
Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784
pubmed: 29923435
Biomed Hub. 2020 May 27;5(2):15-67
pubmed: 32775335
Melanoma Res. 2008 Apr;18(2):152-60
pubmed: 18337653
Melanoma Res. 2018 Feb;28(1):52-55
pubmed: 29120964
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):709-722
pubmed: 34329626
Eur J Health Econ. 2021 Apr;22(3):393-403
pubmed: 33438133
Ann Gastroenterol Surg. 2017 Dec 19;2(1):6-12
pubmed: 29863118
Acta Biomater. 2021 Feb;121:134-142
pubmed: 33301981
Lancet Reg Health Eur. 2021 Jan 29;3:100049
pubmed: 34557799
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Curr Oncol. 2012 Jun;19(3):e165-76
pubmed: 22670106
J Thorac Oncol. 2021 Oct;16(10):1610-1621
pubmed: 34561034
Mol Oncol. 2021 Jun;15(6):1647-1666
pubmed: 33289351
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011
Front Oncol. 2021 Mar 24;11:642112
pubmed: 33842350
Eur J Breast Health. 2019 Oct 01;15(4):242-248
pubmed: 31620683
Gac Sanit. 2020 Mar - Apr;34(2):133-140
pubmed: 31027840
Cancer. 2021 Jul 1;127(13):2262-2270
pubmed: 33764524
Transl Lung Cancer Res. 2021 May;10(5):2395-2406
pubmed: 34164287
Clin Endosc. 2018 Jan;51(1):37-49
pubmed: 29397655
Acta Dermatovenerol Croat. 2021 Apr;291(1):58
pubmed: 34477068
N Engl J Med. 2022 Jun 23;386(25):2363-2376
pubmed: 35660797
J Natl Cancer Inst. 2010 Apr 7;102(7):456-63
pubmed: 20220104
Eur J Cancer. 2017 Apr;75:313-322
pubmed: 28264791
JAMA Dermatol. 2015 Oct;151(10):1087-95
pubmed: 26061591

Auteurs

Denis Horgan (D)

European Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.

Anne-Marie Baird (AM)

Lung Cancer Europe, 3008 Bern, Switzerland.
School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin 2, Ireland.

Mark Middleton (M)

Department of Oncology, Cancer Research UK Oxford Centre, University of Oxford, Oxford OX3 7DQ, UK.

Zhasmina Mihaylova (Z)

Department of Medical Oncology, Military Medical Academy, 1000 Sofia, Bulgaria.

Jan P Van Meerbeeck (JP)

Department of Thoracic Oncology, Antwerp University Hospital, 2650 Edegem, Belgium.

Jens Vogel-Claussen (J)

Department of Diagnostic and Interventional Radiology, Hannover Medical School, 30625 Hannover, Germany.
Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover Medical School, 30625 Hannover, Germany.

Paul E Van Schil (PE)

Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Antwerp University, 2650 Antwerp, Belgium.

Josep Malvehy (J)

Melanoma Unit, Dermatology Department Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
IDIBAPS, CIBER de Enfermedades Raras, Instituto Carlos III, 28029 Madrid, Spain.

Paolo Antonio Ascierto (PA)

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 80131 Naples, Italy.

France Dube (F)

Astra Zeneca, 1800 Concord Pike, Wilmington, DE 19803, USA.

Michael Zaiac (M)

Novartis Farma SpA, 21040 Origgio, Italy.

Jonathan A Lal (JA)

Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
Institute for Public Health Genomics, Department of Genetics and Cell Biology, GROW School of Oncology and Developmental Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The Netherlands.

Grażyna Kamińska-Winciorek (G)

Department of Bone Marrow Transplantation and Hematology-Oncology, Skin Cancer and Melanoma Team, M. Sklodowska-Curie National Research Institute of Oncology, 44-101 Gliwice, Poland.

Marco Donia (M)

National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, 2730 Herlev, Denmark.

Thierry André (T)

Department of Medical Oncology, Sorbonne Université, Hôpital Saint-Antoine, AP-HP, 75012 Paris, France.

Marta Kozaric (M)

European Alliance for Personalised Medicine, 1040 Brussels, Belgium.

Pia Osterlund (P)

Department of Oncology, Tampere University Hospital, 33520 Tampere, Finland.
Department of Upper GI Cancer, Karolinska University Hospital and Institute, 171 76 Stockholm, Sweden.

Dan Lucian Dumitrascu (DL)

Semiology Departement, 2nd Medical Clinic, University of Medicine and Pharmacy "Iuliu Hatieganu", 400347 Cluj-Napoca, Romania.

Luca Bertolaccini (L)

Division of Thoracic Surgery, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.

Classifications MeSH